Sign In
Buy DRMA
$1.27
-0.0900 (-6.62%)
At Close: Jun 03, 2026
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
04:05pm, Wednesday, 13'th May 2026
- Dermata announced their Tome Skincare brand for direct-to-consumer ("DTC") skincare products - - Dermata plans to launch its first DTC product, the Tome Foundational Treatment, a once-weekly mask to
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers - - The Company also has allowed and issued patents in the US, Australi
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
05:15pm, Thursday, 26'th Mar 2026
- Dermata announced a strategic pivot to develop and commercialize direct-to-consumer ("DTC") skincare products under the brand name Tome - - Dermata plans to launch its first DTC product, our Foundat
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
01:12am, Saturday, 21'st Mar 2026
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
08:30am, Tuesday, 10'th Mar 2026
- Kyra Peckaitis will lead the launch of Dermata's recently announced Tome skincare brand - SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / Dermata Therapeutics, Inc. ("Dermata," or the "Company")
Dermata Therapeutics (DRMA) Projected to Post Earnings on Monday
02:36am, Monday, 09'th Mar 2026
Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) is expected to issue its results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($1.54) per sh
Dermata Opens a New Chapter with the Release of Tome Skincare
09:00am, Thursday, 05'th Mar 2026
-The oldest new thing in skincare - - Dermata expects to launch its first product in the middle of 2026 - SAN DIEGO, CA / ACCESS Newswire / March 5, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nas
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
08:05am, Tuesday, 20'th Jan 2026
This patent grant follows the Company's U.S. issued patent, covering its Spongilla technology combination as a method to topically treat acne Dermata expects to launch a new once-weekly, over-the-coun
Stock Market Today: S&P 500, Dow Jones Futures Trade Mixed Amid Blip In Santa Claus Rally—Boeing, Freeport-McMoRan, Fonar In Focus
05:21am, Tuesday, 30'th Dec 2025
U.S. stock futures swung between gains and losses on Tuesday after Monday's declines. Futures of major benchmark indices were mixed. The Santa Claus rally, which began on Dec. 24 last week, seems to h
Verastem, TEN Holdings And 3 Stocks To Watch Heading Into Tuesday
12:54am, Tuesday, 30'th Dec 2025
U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, CapsoVision down 11%.
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
04:05pm, Monday, 29'th Dec 2025
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 29, 2025 / Dermata Th
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:00am, Wednesday, 24'th Dec 2025
$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / December 24, 2025 / Dermata Th
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
08:00am, Thursday, 04'th Dec 2025
SAN DIEGO, CA / ACCESS Newswire / December 4, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today annou
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:05pm, Friday, 14'th Nov 2025
- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments - - Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongi
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
08:00am, Thursday, 02'nd Oct 2025
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne - - Dermata expects to launch a new once-weekly, Over-the-Coun
